|Poll|April 29, 2014

What Cause of an Ulcer after Roux-en-Y Bypass Surgery?

This 42-year-old woman lost 100 lb during the year after gastric bypass surgery. Now, she is diagnosed as having an ulcer. What might be the cause of the lesion?

A 42-year-old woman presents to the hospital with epigastric pain of several weeks’ duration. She underwent a Roux-en-Y gastric bypass procedure 1 year ago and subsequently lost 100 lb. She undergoes an upper endoscopy for evaluation which demonstrates an ulcer at the gastro-jejunal junction.

What is the most likely cause of the ulcer?

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

What Cause of an Ulcer after Roux-en-Y Bypass Surgery?

Newsletter

Related Content

FDA Approves Simplified Once-Monthly Mirikizumab-mrkz Regimen for Ulcerative Colitis Maintenance Therapy

GLP-1 Receptor Agonist GI Safety Comparable Within the Class, But Exceeds SGLT-2 Inhibitor Risk

Non-Celiac Gluten/Wheat Sensitivity Affects 1 in 10 Globally, Often with Comorbid IBS

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment

FDA OKs Subcutaneous Guselkumab Regimen for Ulcerative Colitis: Daily Dose

Latest CME

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Nevada

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arkansas

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

20th Annual Controversies in Modern Eye Care

Addressing Unmet Needs in HER2+ Metastatic BTC

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) Collaborating Across the Continuum™: Best Practices in Patient-Centric Team Management of XLRP

(CME Track) The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Pathways to Progress: RAS in GI Cancers (Spotlight CE Session)

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Tackling Barriers to Vaccine Uptake: Practical Strategies for Adult Immunization

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Burst CME CGM: Continuous Glucose Monitoring Considerations – Maximizing Quality of Life for Patients

26th Annual International Lung Cancer Congress

Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

(CME Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

(COPE Track) Beyond the Collarette: Empowering Patients in the Management of Demodex Blepharitis

IgAN Case Files: Real Conversations, Evolving Evidence

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Identifying and Treating Generalized Myasthenia Gravis in the Modern Era

Addressing Unmet Needs for Patients With Spinal Muscular Atrophy—Understanding Patient Challenges and Management Approaches

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Navigating Ocular Toxicities: A Multidisciplinary Roadmap for Managing Adverse Events in Targeted Cancer Therapy

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Clinical Consultations™: Tailoring Treatment for Cystic Fibrosis (CF) Across Life Stages and Evolving Health Needs

A Shield of Protection: Unmet Needs in COVID-19 Prevention and Control

21st Annual New York Lung Cancers Symposium®

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Derm Nexus The Inflammatory Disease and Innovations Congress for NP/PAs

Expert Illustrations & Commentaries™: Visualizing the Role of B Cells as Therapeutic Targets for Generalized Myasthenia Gravis

9th Annual School of Nursing Oncology™

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

(Pharmacist Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

GI Cancers Symposia

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Arizona

2nd Annual Hawaii Cancer Conference

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies